Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.68 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this epilepsy drug developer would post a loss of $0.64 per share when it actually produced a loss of $0.74, delivering a surprise of -15.63%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Marinus Pharmaceu ...